Keystone Corporation

Keystone Bio is a clinical-stage biotechnology company pioneering a new class of biotherapeutics and diagnostics targeting the "Keystone Pathogen," Porphyromonas gingivalis (Pg). The company's lead candidate, KB-001, is a first-in-class monoclonal antibody designed to eliminate virulent Pg from the oral cavity, thereby preventing the systemic dissemination of toxic gingipains that drive chronic inflammation and diseases such as Alzheimer's and atherosclerosis. By addressing the oral-systemic link, Keystone Bio aims to provide a precision medicine approach to treating and preventing major inflammatory and neurodegenerative conditions. The company's strategy integrates dentistry and medicine to shut down systemic inflammation at its source.